期刊
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
卷 39, 期 4, 页码 877-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2013.06.001
关键词
Juvenile myositis; Juvenile dermatomyositis; Juvenile polymyositis; Overlap myositis; Myositis-specific autoantibodies; Treatment; Biologic therapies
类别
资金
- Intramural Research Program of the NIH, National Institute of Environmental Health
This review updates recent trends in the classification of the juvenile idiopathic inflammatory myopathies (JIIM) and the emerging standard of treatment of the most common form of JIIM, juvenile dermatomyositis. The JIIM are rare, heterogeneous autoimmune diseases that share chronic muscle inflammation and weakness. A growing spectrum of clinicopathologic groups and serologic phenotypes defined by the presence of myositis autoantibodies are now recognized, each with differing demographics, clinical manifestations, laboratory findings, and prognoses. Although daily oral corticosteroids remain the backbone of treatment, disease-modifying anti-rheumatic drugs are almost always used adjunctively and biologic therapies may benefit patients with recalcitrant disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据